CUE
Cue Biopharma
25.50$
-7.1%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | 2,498.2% | 794.9% | 1,063.5% | -11.9% | 145.1% | 693.9% | 25.3% | 12.7% | |
| – | – | – | -2,398.2% | 100.0% | -963.5% | 100.0% | 100.0% | -593.9% | 100.0% | 100.0% | |
| – | – | – | 2,498.2% | 794.9% | 1,063.5% | 276.7% | 3,098.6% | 743.2% | 390.8% | 137.4% | |
| – | – | – | 988.5% | 368.4% | 464.5% | 115.8% | 1,298.7% | 303.8% | 157.0% | 59.1% | |
| – | – | – | 3,486.7% | 1,163.3% | 464.5% | 392.6% | 4,375.1% | 356.0% | 546.9% | 196.6% | |
| – | – | – | -3,386.7% | -1,063.3% | -1,428.0% | -292.6% | -4,275.1% | -949.9% | -446.9% | -96.6% | |
| – | – | – | 0.0% | 163.3% | 14.7% | 11.6% | 57.3% | 22.7% | 8.6% | 1.3% | |
| – | – | – | -3,339.3% | -1,049.3% | -1,413.3% | -292.3% | -4,257.8% | -924.1% | -438.0% | -95.0% | |
| – | – | – | 72.2% | 11.9% | 6.5% | 3.3% | -17.2% | 59.5% | -438.0% | 1.8% | |
| – | – | – | -3,411.5% | -1,061.2% | -1,419.8% | -295.6% | -4,257.8% | -924.1% | -438.0% | -96.9% | |
| – | – | – | -3,320.2% | -913.9% | -1,394.4% | -304.5% | -4,055.5% | -838.8% | -404.1% | -81.1% |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.